Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231375 | 0.86 | AR (0.75) | ARPGRNR3C2 | |
| SCHEMBL14409343 | 0.82 | AR (0.69) | ARPGRNR3C2 | |
| SCHEMBL19236106 | 0.77 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL2865965 | 0.76 | AR (0.61) | ARPGRNR3C2 | |
| SCHEMBL29474210 | 0.76 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL5233514 | 0.75 | AR (0.93) | ARPGRNR3C2 | |
| SCHEMBL5229536 | 0.74 | AR (0.65) | ARPGRNR3C2 | |
| SCHEMBL5231908 | 0.74 | AR (0.65) | ARPGRNR3C2 | |
| SCHEMBL5229542 | 0.74 | AR (0.65) | ARPGRNR3C2 | |
| SCHEMBL6336245 | 0.72 | AR (0.56) | ARPGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | claimed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | claimed |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | ZHI LIN | 2006-06-15 | — | — | US | claimed |
| EP-1363909-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | claimed |
| WO-2002066475-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | claimed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-15 | — | — | US | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | ZHI LIN | 2006-06-15 | — | — | US | disclosed |
| US-7026484-B2 | For therapy of cancer | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-04-11 | — | — | US | disclosed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885NR3C2 33/4885 |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885NR3C2 33/4885 |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C2 14/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885NR3C2 33/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885NR3C2 33/4885 |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C2 14/4885 |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 46/4885NR3C2 14/4885 |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C2 14/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885NR3C2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.